Safety and diagnostic efficacy of cone beam computed tomography-guided transbronchial cryobiopsy for interstitial lung disease: a cohort study

To the Editor:

Transbronchial cryobiopsy (TBCB) is one of the most important procedures for assessment of patients with suspected interstitial lung disease (ILD), when diagnosis cannot be made based on clinical and radiological assessments [1–4]. Recent reports suggested that TBCB may offer diagnostic value approaching that of surgical lung biopsy [5, 6].

The location of the cryobiopsy is strongly associated with procedure-related complications [2, 3]. Chest fluoroscopy has been suggested by some clinicians [2, 3] to guide TBCB. However, the probe-to-pleura distance is unclear when the probe path is not perpendicular to the P-A plane of the C-arm imaging. A recent meta-analysis [7] observed an overall complication rate of 23.1%, with significant bleeding and pneumothorax reported in 14.2% and 9.4% of patients, respectively. Compared to fluoroscopy, cone-beam computed tomography (CBCT) can provide three-dimensional (3D) computed tomography (CT) images that approach the image qualities of conventional CT [8]. Using this approach, the probe-to-pleura relationship can be accurately established based on 3D scans, which may improve the safety profile of cryobiopsies. We thus conducted a single-centre prospective cohort study (NCT04047667) which was approved by our institution's human research ethics committee.

All patients diagnosed with ILD between September 2018 and August 2019 who met the following eligibility criteria were recommended to undergo CBCT-guided TBCB: >18 years of age; a diagnosis of ILD could not be established after integration of clinical features; forced vital capacity (FVC) >50%; and diffusing capacity of the lung for carbon monoxide (D_{LCO}) >35%. Patients who met the following criteria were excluded: acute exacerbation in the past 30 days, bleeding diathesis, anticoagulant therapy, current use of antiplatelet drugs, pulmonary hypertension, respiratory failure, liver or kidney disfunction, cardiac insufficiency and platelet count $<50\times10^9$ per L. Written informed consent was obtained from all patients prior to enrolment in the study.

Bronchoscopies were performed through endotracheal tube or rigid bronchoscopy under general anaesthesia in a hybrid CBCT operation room. Cryoprobe (ERBE, Solingen, Germany) was advanced as far as possible into the target bronchial segment through the bronchoscopy working channel. The cryoprobe was then retracted 1 cm and the bronchoscopy was fixed on a stand. All medical workers were then moved to the control room and CBCT imaging (Artis Zee III ceiling, Siemens AG, Munich, Germany) was performed. 3D CT images were acquired and reviewed in axial, coronal and sagittal planes to accurately assess the cryoprobe position (figure 1a) within the lung parenchyma and relative to other thoracic structures. Re-positioning of cryoprobe was conducted if necessary to ensure a probe-to-pleura distance of ~1 cm. Cryobiopsy was performed (6–8 s freeze time for 1.9 mm cryoprobe and 4–6 s for 2.4 mm cryoprobe) following probe positioning, using carbon dioxide as the cryogen. After each biopsy, a bronchial blocker was immediately filled to stop the bleeding. Post-procedure CBCT or radiography was used to screen for acute pneumothorax. Bleeding severity was graded on the scale described by Ernst *et al.* [9].

@ERSpublications
Cone beam CT (CBCT) can provide 3-dimensional images enabling accurate positioning of cryoprobe. CBCT-guided transbronchial cryobiopsy had a favourable safety profile with low risks of pneumothorax and significant bleeding, with excellent diagnostic yield. https://bit.ly/2WF0SPF

Cite this article as: Zhou G, Ren Y, Li J, *et al*. Safety and diagnostic efficacy of cone beam computed tomography-guided transbronchial cryobiopsy for interstitial lung disease: a cohort study. *Eur Respir J* 2020; 56: 2000724 [https://doi.org/10.1183/13993003.00724-2020].



b) Patient characteristics

Patients	155
Median age years	55.2±12.1
Male-to-female (ratio)	90/65 (1.4)
Smokers	73 (47.1%)
Environmental or occupational history	55 (34.5%)
Mean FVC % predicted	88.6±20.5
Mean D_{LCO} % predicted	68.0±19.5
HRCT pattern	
Fibrotic	67 (43.2%)
Non-fibrotic	88 (56.8%)
Cryoprobe	
1.9 mm	48 (31.0%)
2.4 mm	107 (69.0%)
Biopsy site	
Single segment	72 (46.5%)
Multiple segments	83 (53.5%)
Mean sample number	3.39±0.96
Mean sample size	
Surface area mm^2	24.5±11.1
Long axis diameter mm	5.4±1.4
Short axis diameter mm	4.3±1.1
Mean CBCT scanning times	2.1±0.7
Cryoprobe re-position after CBCT	66 (42.6%)
Radiation exposure mSv	17.0±7.0
Procedure duration min	38.5±15.3

c) Outcomes of CBCT-guided TBCB

Patients	155
Complication	
Pneumothorax	3 (1.9%)
Mild bleeding	116 (74.8%)
Moderate bleeding	19 (12.3%)
Acute exacerbation of ILD	1 (0.6%)
Post-bronchoscopy fever	11 (7.1%)
Diagnostic yields	
Pathological diagnosis	134 (86.5%)
MDD diagnosis	140 (90.3%)

FIGURE 1 a) Three-dimensional (3D) cone beam computed tomography (CBCT) images used to identify the cryoprobe position. b) Clinical characteristics in patients with interstitial lung disease (ILD) undergoing CBCT-guided transbronchial cryobiopsy (TBCB). c) Safety and diagnostic outcomes of CBCT-guided TBCB. MDD: multidisciplinary discussion; FVC: forced vital capacity; D_{LCO}: diffusing capacity of the lung for carbon monoxide; HRCT: high-resolution computed tomography. Data are presented as mean±SD, unless otherwise stated.

Intensive care unit admission, histopathological diagnosis, and multidisciplinary discussion (MDD) diagnosis, disease progression and death within 30-day after TBCB were followed up.

A total of 155 patients (male-to-female ratio 1.4; 90/65) were finally enrolled (figure 1b), with a mean±SD age of 55.2±12.1 years; FVC was 88.6%±20.5% and D_{LCO} was 68.0%±19.5%. Fibrotic patterns on high-resolution CT (HRCT) were found in 67 (43.2%) patients.

Prior to TBCB, 66/155 (42.6%) patients required re-positioning after CBCT guidance. The mean±SD number of CBCT scans conducted throughout the procedure was 2.1±0.7, with a radiation exposure of 17.0±7.0 mSv. The radiation exposure significantly decreased from 18.7±0.8 mSv to 10.6±1.4 mSv in the groups receiving post-procedure CBCT and radiography, respectively (t-test, p<0.001). All medical staff were free of radiation exposure.

A mean±SD of 3.39±0.96 specimens was obtained, with a surface area of 24.5±11.1 mm^2 (long axis diameter: 5.4±1.4 mm, short axis diameter 4.3±1.1 mm). A specific pathological diagnosis (P-diagnosis) was achieved in 134/155 patients (86.5%): 32 (20.6%) had non-specific interstitial pneumonia (NSIP), 19 (12.3%) had usual interstitial pneumonia and 15 (9.7%) had hypersensitivity pneumonitis (HP). An MDD diagnosis was possible in 140/155 patients (90.3%): 28 (18.1%) had connective tissue disease-related ILD, 23 (14.8%) had HP, 18 (11.6%) had idiopathic pulmonary fibrosis and 17 (11.0%) had NSIP. The agreement between P-diagnosis and MDD diagnosis was 80.0%, with a corresponding kappa concordance coefficient of 0.78 (95% CI 0.75–0.80).

The complications of CBCT-guided TBCB are summarised in figure 1c. The most common complication was procedure-related bleeding. 20 patients (12.9%) had no bleeding; others had either mild (116/155, 74.8%) or moderate (19/155, 12.3%) bleeding that was immediately controlled by endoscopic measures. No severe bleeding events were reported. Pneumothorax occurred in only three patients (1.9%); all instances

were resolved using a chest tube and cured within 1 week; one of them presented visceral pleura in samples. Acute exacerbation of ILD and temporary post-bronchoscopy fever occurred in one (0.6%) and 11 (7.1%) patients, respectively. No deaths were reported within 30 days after TBCB.

Multivariate logistic regression analyses indicated that a reduced number of biopsies collected (p=0.007) and fibrotic patterns on HRCT (p=0.002) may be associated with a greater risk of moderate bleeding. No significant associations were observed between various clinical features and the risk of pneumothorax or diagnostic efficacy.

To our best knowledges, this report represents the first prospective study of CBCT-guided TBCB, revealing favourable safety and diagnostic profiles.

Pneumothorax is one of the most common complications of TBCB. Occurrence of pneumothorax could lead to longer hospital stay and increased medical cost [6]. In some reported studies, pneumothorax was a serious, life-threatening complication, which resulted in several deaths [10–13]. Fluoroscopic guidance is presumed to reduce the incidence of pneumothorax by localising the cryoprobe at a suitable position and is routinely used in TBCB [2, 3]. However, numerous studies have shown that fluoroscopy does not significantly reduce the rate of pneumothorax. In a large retrospective cohort study by Ravaglia *et al.* [14], pneumothorax occurred in 19.2% (134/699) of patients after fluoroscopy-guided TBCB, of which 70.1% required chest tube drainage. These analyses suggest that the rate of pneumothorax might be significantly higher in fluoroscopy-guided TBCB than in CBCT-guided procedures. Here, we found the incidence of pneumothorax was only 1.9%. The 3D images generated by CBCT presented an accurate view of the cryoprobe position, enabling us to measure the probe-to-pleura distance. Of the 155 patients enrolled in this study, 66 (42.6%) required repositioning of the cryoprobe prior to biopsy, enabling an optimal probe-to-pleura distance of ∼1 cm. Furthermore, the precise localisation of cryobiopsy under guidance of 3D CBCT imaging might reduce the influences of clinical factors on pneumothorax. We found no apparent relationship between the rate of pneumothorax and biopsy sites, cryoprobe types or sample sizes. This was different from a previous study [13] which showed collection of >1 biopsy or use of a 2.4 mm cryoprobe could significantly increase the rate of pneumothorax, even under fluoroscopy guidance.

Bleeding is another common complication encountered in TBCB; the incidence of serious bleeding events has ranged from 0% to 42%. There were no severe bleeding events reported in our study; however, moderate bleeding was observed in 12.3% of patients. Accurate localisation by CBCT 3D imaging might be helpful to prevent severe bleeding, as it enabled a consistent cryoprobe-to-pleura distance of ∼1 cm, targeting an area that primarily contained only small vessels. Multivariate analysis suggested that fewer TBCB biopsies and fibrotic patterns on HRCT may be associated with a higher risk of moderate bleeding. The former could be explained by the occurrence of moderate bleeding leading to discontinuation of further biopsy collection. The latter may tell us that it is important to assess fibrotic score on HRCT before TBCB in order to prevent significant bleeding risk.

The use of CBCT guidance significantly reduced TBCB-related complications, with 42.6% of patients requiring repositioning based on CBCT images. However, the addition of CBCT to TBCB may increase radiation exposure for patients, compared to fluoroscopy. In our study, only one CBCT scan was conducted for TBCB procedures in the same lobe, thereby reducing radiation exposure. To optimise probe placement without repeated CBCT scanning, optimisation of the probe-to-pleura distance was achieved by repositioning the cryoprobe based on the difference between actual and predicted positions. Subsequent samples in the same area or adjacent segment were then obtained by inserting the cryoprobe at consistent intervals from the location of the first biopsy. As a result, we performed a mean of 3.39 samples per patient, with a mean of only 1.1 CBCT scans necessary to guide TBCB. Furthermore, replacement of post-procedure CBCT with a traditional radiograph significantly reduced the mean radiation exposure to 10.6 mSv.

To the best of our knowledge, this work constitutes the largest cohort study thus far regarding the use of CBCT guidance for bronchoscopy. However, it is limited by its non-randomised controlled design.

In conclusion, CBCT-guided TBCB was associated with a favourable safety profile, with low risks of pneumothorax and moderate-to-severe bleeding. Both histopathological and MDD diagnostic yield were excellent, with a high level of agreement between these metrics.

Guowu Zhou[1], Yanhong Ren[1], Jun Li[1], Ting Yang[1], Nan Su[1], Ling Zhao[2], Dan Wang[1], Ying Li[1], Zheng Tian[1], Ruihong Liu[1], Huaping Dai[1] and Chen Wang[1,3]

[1]Dept of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China. [2]Dept of Pathology, China-Japan Friendship Hospital, Beijing, China. [3]Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.

Correspondence: Huaping Dai, Dept of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, 2 Yinghuayuan East Street, Chaoyang District, Beijing 100029, China. E-mail: daihuaping@ccmu.edu.cn

Received: 14 Jan 2020 | Accepted after revision: 19 March 2020

Conflict of interest: None declared.

Support statement: This study was supported by National Key Technologies R & D Program Precision Medicine Research (number 2016YFC0901101), CAMS Innovation Fund for Medical Sciences (CIFMS, number 2018-12M-1-001), Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (number 2019PT320021), and Beijing Municipal Science and Technology Commission (Z161100000516090). Funding information for this article has been deposited with the Crossref Funder Registry.

References

1 Babiak A, Hetzel J, Krishna G, *et al.* Transbronchial cryobiopsy: a new tool for lung biopsies. *Respiration* 2009; 78: 203–208.
2 Hetzel J, Maldonado F, Ravaglia C, *et al.* Transbronchial cryobiopsies for the diagnosis of diffuse parenchymal lung diseases: expert statement from the Cryobiopsy Working Group on Safety and Utility and a call for standardization of the procedure. *Respiration* 2018; 95: 188–200.
3 Maldonado F, Danoff SK, Wells AU, *et al.* Transbronchial cryobiopsy for the diagnosis of interstitial lung diseases: CHEST guideline and expert panel report. *Chest* 2020; 157: 1030–1042.
4 Raghu G, Remy-Jardin M, Myers JL, *et al.* Diagnosis of idiopathic pulmonary fibrosis. an official ATS/ERS/JRS/ALAT clinical practice guideline. *Am J Respir Crit Care Med* 2018; 198: e44–e68.
5 Troy LK, Grainge C, Corte TJ, *et al.* Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study. *Lancet Respir Med* 2020; 8: 171–181.
6 Tomassetti S, Wells AU, Costabel U, *et al.* Bronchoscopic lung cryobiopsy increases diagnostic confidence in the multidisciplinary diagnosis of idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2016; 193: 745–752.
7 Sethi J, Ali MS, Mohananey D, *et al.* Are transbronchial cryobiopsies ready for prime time? A systematic review and meta-analysis. *J Bronchology Interv Pulmonol* 2019; 26: 22–32.
8 Hohenforst-Schmidt W, Zarogoulidis P, Vogl T, *et al.* Cone beam computertomography (CBCT) in interventional chest medicine – high feasibility for endobronchial realtime navigation. *J Cancer* 2014; 5: 231–241.
9 Ernst A, Eberhardt R, Wahidi M, *et al.* Effect of routine clopidogrel use on bleeding complications after transbronchial biopsy in humans. *Chest* 2006; 129: 734–737.
10 Casoni GL, Tomassetti S, Cavazza A, *et al.* Transbronchial lung cryobiopsy in the diagnosis of fibrotic interstitial lung diseases. *PLoS One* 2014; 9: e86716.
11 Echevarria-Uraga JJ, Pérez-Izquierdo J, García-Garai N, *et al.* Usefulness of an angioplasty balloon as selective bronchial blockade device after transbronchial cryobiopsy. *Respirology* 2016; 21: 1094–1099.
12 Hagmeyer L, Theegarten D, Treml M, *et al.* Validation of transbronchial cryobiopsy in interstitial lung disease - interim analysis of a prospective trial and critical review of the literature. *Sarcoidosis Vasc Diffuse Lung Dis* 2016; 33: 2–9.
13 Sriprasart T, Aragaki A, Baughman R, *et al.* A single US center experience of transbronchial lung cryobiopsy for diagnosing interstitial lung disease with a 2-scope technique. *J Bronchology Interv Pulmonol* 2017; 24: 131–135.
14 Ravaglia C, Wells AU, Tomassetti S, *et al.* Diagnostic yield and risk/benefit analysis of trans-bronchial lung cryobiopsy in diffuse parenchymal lung diseases: a large cohort of 699 patients. *BMC Pulm Med* 2019; 19: 16.